Executive Summary

Q2 FY2025: Net loss was $15.73M ($-0.22 EPS), with R&D $12.63M and G&A $4.45M; cash and investments totaled $105.3M at 12/31/24, reflecting continued funding of Phase 3 programs .
Regulatory momentum strengthened: FDA granted Breakthrough Therapy Designation (BTD) for congenital HI and Orphan Drug Designation (ODD) for tumor HI, while the DMC validated infant dosing and safety in sunRIZE’s open-label arm .
Program timelines refined: U.S. enrollment for sunRIZE anticipated in Q2 2025; topline results expected in Q4 2025, subject to an interim analysis (IA) that could trigger a 33% sample size increase and shift topline to mid-2026 if enacted .
No earnings call transcript was available for Q2 FY2025; comparisons to Wall Street consensus are unavailable due to S&P Global data limitations (pre-revenue profile) .

What Went Well and What Went Wrong

What Went Well

BTD for ersodetug in congenital HI and ODD in tumor HI, de-risking regulatory pathways and potentially expediting development .
DMC review in infants confirmed target exposures and safety, enabling infant enrollment into the double-blind portion; dosing regimen (5–10 mg/kg) validated .
Management reiterated focus and momentum: “We have made significant regulatory progress… focus in 2025 remains squarely on advancing both Phase 3 trials” — Nevan Charles Elam, CEO .

What Went Wrong

Operating expenses rose YoY (Total OpEx $17.08M vs $15.19M), widening net loss YoY ($15.73M vs $13.91M) amid increased clinical, manufacturing, and personnel costs .
Timeline risk surfaced: IA could mandate a 33% sample size increase, pushing sunRIZE enrollment completion to Q4 2025 and topline to mid-2026 (if enacted) .
U.S. enrollment timing refined later within 1H 2025 (from “early 2025” to “Q2 2025”), reflecting operational sequencing and DMC gating .

Financial Results

P&L (in $USD Millions, except EPS)

Metric	Q2 2024 (Dec 31, 2023)	Q1 2025 (Sep 30, 2024)	Q2 2025 (Dec 31, 2024)
Research and development	$12.04	$12.75	$12.63
General and administrative	$3.16	$4.19	$4.45
Total operating expenses	$15.19	$16.94	$17.08
Non-operating income, net	$1.29	$1.56	$1.35
Net loss	$13.91	$15.38	$15.73
Basic & diluted EPS ($)	$-0.27	$-0.22	$-0.22

Notes: Company did not report product revenue; condensed statements present operating expenses and net loss components only for these periods .

Balance Sheet Snapshot (in $USD Millions)

Metric	Q4 2024 (Jun 30, 2024)	Q1 2025 (Sep 30, 2024)	Q2 2025 (Dec 31, 2024)
Cash and cash equivalents	$70.40	$10.47	$8.93
Investments in marketable debt securities	$56.74	$107.35	$96.38
Working capital	$119.05	$102.19	$88.09
Total assets	$132.74	$123.41	$112.01
Total stockholders’ equity	$121.00	$113.44	$99.59

Guidance Changes

Metric	Period	Previous Guidance	Current Guidance	Change
sunRIZE U.S. enrollment start	1H 2025	“U.S. participants in early 2025”	“U.S. participants anticipated in Q2 2025”	Refined later in 1H (timing shifted)
sunRIZE overall enrollment completion	2025	N/A	“Expected to conclude in Q2 2025, subject to IA”	New specific timing
sunRIZE topline results	2025	“Second half of 2025”	“Q4 2025, subject to IA outcomes”	Narrowed window; conditional on IA
sunRIZE interim analysis	Q1–Q2 2025	N/A	IA at end of this quarter; 3 outcomes incl. +33% sample size	New gating event introduced
Tumor HI Phase 3 start	1H 2025	“Anticipated to begin in 1H 2025”	“Anticipated to begin in 1H 2025”	Maintained
Tumor HI topline	2026	“Second half of 2026”	“Second half of 2026”	Maintained

Earnings Call Themes & Trends

Topic	Previous Mentions (Q4 2024, Q1 2025)	Current Period (Q2 2025)	Trend
Regulatory designations	FDA lifted partial clinical holds; IND cleared for tumor HI	BTD for congenital HI; ODD for tumor HI	Strengthening regulatory momentum
sunRIZE timeline	Topline expected 2H 2025; U.S. site start-up underway	U.S. enrollment Q2 2025; topline Q4 2025 subject to IA	Timeline refined; IA introduces conditionality
Infant cohort safety/PK	Not previously detailed	DMC validated infant dosing (5–10 mg/kg) and safety; exposures aligned with Phase 2b	Positive safety validation; dosing confirmed
Tumor HI program	IND cleared; start expected 1H 2025	ODD granted; start 1H 2025, topline 2H 2026	Advancing per plan; designation adds value
R&D execution	R&D spend elevated in Q4 FY2024 with manufacturing/milestones	R&D stable QoQ; higher YoY; G&A up with headcount/pro fees	Controlled sequential spend; YoY growth continues
Financing/runway	Cash/investments $127.1M at 6/30/24; strengthened balance sheet	Cash+investments $105.3M at 12/31/24; prior $73M raise supports into Q2 2026	Adequate runway to major readouts

Management Commentary

“We have made significant regulatory progress with ersodetug and our focus in 2025 remains squarely on advancing both Phase 3 trials for patients with congenital HI and tumor HI.” — Nevan Charles Elam, CEO .
“We are encouraged by these preliminary outcomes from the open label arm of the sunRIZE study… strong indication of the safety profile of ersodetug and… validation of the selected doses in very young participants.” — Brian Roberts, M.D., CMO .
“Execution across our two Phase 3 programs in patients with congenital HI and tumor HI will be the focus going into 2025… we recognize how critical 2025 will be in progressing our programs.” — Nevan Charles Elam, CEO .

Q&A Highlights

No Q2 FY2025 earnings call transcript was available in the document set; management commentary was provided via press releases and the 8‑K exhibit .

Estimates Context

Wall Street consensus (S&P Global) EPS and revenue estimates for Q2 FY2025 were unavailable at the time of analysis; the company does not report product revenue and did not provide financial guidance, so comparisons to consensus could not be made .

Key Takeaways for Investors

Regulatory de-risking: BTD (congenital HI) and ODD (tumor HI) enhance probability-weighted timelines and potential approval pathways; these are meaningful catalysts for sentiment and valuation .
Near-term catalyst: DMC IA conclusion (early Q2 2025) will determine continuation as-is vs. +33% sample size; the latter would extend timelines to mid-2026 for topline, impacting near-term readout expectations .
sunRIZE operational progress: U.S. site activation and Q2 2025 U.S. enrollment should broaden recruitment; overall enrollment conclusion targeted for Q2 2025 barring IA-driven changes .
Infant safety confirmation: DMC validation of dosing and safety in infants improves pediatric risk profile and supports broader age eligibility within sunRIZE .
Cash runway: $105.3M cash+investments at 12/31/24, with prior financing supporting operations into Q2 2026 — sufficient to reach major readouts under base case timelines .
Expense trajectory: Sequentially controlled R&D in Q2 vs Q1 (flat-ish), but higher YoY as clinical and manufacturing activities scale; expect continued spend concentration around Phase 3 execution .
Trading implications: Stock likely sensitive to IA outcome and timing clarity for topline; BTD/ODD underpin the medium-term thesis, but any IA-driven sample size increase would be a near-term overhang until new timelines are absorbed by the market .

Sources: Q2 FY2025 8-K and Exhibit 99.1 press release ; Q1 FY2025 8-K and Exhibit 99.1 ; Q4 FY2024 8-K and Exhibit 99.1 ; sunRIZE DMC/IA press release (Feb 4, 2025) ; BTD press release (Jan 7, 2025) .

Rezolute, Inc. (RZLT)·Q2 2025 Earnings Summary